Camber Pharmaceuticals Launches Generic Phenergan®

Piscataway, NJ, May 3, 2023–Camber Pharmaceuticals is pleased to announce the addition of Promethazine HCI Suppositories, USP to its current portfolio.
Promethazine HCI Suppositories, USP are used to treat allergy symptoms such as itching, runny nose, sneezing, itchy or watery eyes, hives, and itchy skin rashes. It also prevents motion sickness, and treats nausea and vomiting or pain after surgery. It is also used as a sedative or sleep aid.
Click here to read the complete indication and usage for Promethazine HCI Suppositories, USP.
Promethazine HCI Suppositories, USP are available in 12.5 and 25 mg strengths in 12 count boxes.
To find out more about Promethazine HCI Suppositories, USP please visit www.camberpharma.com
Recent articles
- Camber’s Parent Company, Hetero, Partners with the Gates Foundation to Supply Generic Lenacapavir for HIV Prevention
- Camber Adds 800 mg Darunavir Tablets to Product Family
- Camber Expands Portfolio with 10 New Generic Drug Launches in Q3 2025
- Camber Launches Indomethacin Suppositories
- Camber Launches Voriconazole for Injection
- Camber Launches Magnesium Sulfate Injection